Diffuse large B cell lymphoma: prognostic factors in the rituximab era = Linfoma B difuso de células grandes: factores pronósticos en la era del rituximab

Abstract

Introduction: The inclusion of rituximab for treatment of diffuse large B cell lymphoma (DLBCL) generated the need to re-assess the conventionally employed prognostic factors and to explore others that could be useful for prognostic purposes. Objective: To describe the most important clinical, hematological, biochemical and immunohistochemical factors that have been useful for prognostic purposes in follow-up studies of patients with DLBCL treated with chemotherapy plus rituximab. Results: The following factors were found to have prognostic significance: the revised International Prognostic Index, bone marrow infiltration, the presence of a bulky mass, CD5 expression and the percentage of Ki-67 expression. Contrariwise, the application of other factors remains controversial: conventional IPI, Bcl-2 and Bcl-6 expression, and the immunohistochemical profile.

Keywords

• Antígenos CD5
• Beta 2-Microglobulina
• Linfoma de Células B Grandes Difuso
• Antigens
• CD5
• Bone Marrow
• Large B-cell Diffuse Lymphoma
• Migroglobuline beta-2